New combo pill for high cholesterol tested on thousands

NCT ID NCT06314919

Recruiting now Disease control Sponsor: Boryung Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a fixed-dose combination of two cholesterol-lowering drugs, pitavastatin and ezetimibe, in over 8,600 people with high cholesterol or mixed lipid disorders. The goal is to see how well the combo works and how safe it is in real-world conditions, outside of a strict research setting. Participants are already on statins or ezetimibe and are switching to the combo pill.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pitavastatin and Ezetimibe (fixed-dose combination)
What this could lead to: If successful, this could confirm that the fixed-dose combination is effective and safe for managing high cholesterol in everyday practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It also focuses on cholesterol levels, not long-term health outcomes like heart attacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED DYSLIPIDEMIA PRIMARY HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

Ewha Womans University Seoul Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.